Long-Term Efficacy of ⁹⁰Y-Dotatate in Patients with Nonresectable Pancreatic and Small Bowel Neuroendocrine Neoplasms

ABSTRACT

Aim: To determine the efficacy of ⁹⁰Y [DOTA⁰, D-Phe¹, Tyr³]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response. Results: Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient’s gender. Conclusion:⁹⁰Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes.

KEYWORDS:

• ⁹⁰Y-DOTATATE therapy
• clinical and radiological response
• GEP-NET

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Editing assistance was provided by David P Figgitt, Content Ed Net, funded by the authors.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.